Literature DB >> 23714526

Monitoring and managing minimal residual disease in acute lymphoblastic leukemia.

Dieter Hoelzer1.   

Abstract

In adult acute lymphoblastic leukemia (ALL) the complete remission (CR) rates have improved to 85% to 90%. Despite this high CR rate, 40% to 50% of patients eventually relapse. This occurs because of the limited sensitivity of cytomorphology in assessing complete molecular remission. Thus, more sensitive methods that detect leukemic cells on a molecular level and identify minimal residual disease are needed.

Entities:  

Mesh：

Year:  2013        PMID： 23714526     DOI： 10.14694/EdBook_AM.2013.33.290

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


  5 in total

1.  Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.

Authors:  S Nishiwaki; K Imai; S Mizuta; H Kanamori; K Ohashi; T Fukuda; Y Onishi; S Takahashi; N Uchida; T Eto; H Nakamae; T Yujiri; S Mori; T Nagamura-Inoue; R Suzuki; Y Atsuta; J Tanaka
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

2.  Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.

Authors:  Satoshi Nishiwaki; Yu Akahoshi; Shuichi Mizuta; Akihito Shinohara; Shigeki Hirabayashi; Yuma Noguchi; Takahiro Fukuda; Naoyuki Uchida; Masatsugu Tanaka; Makoto Onizuka; Yukiyasu Ozawa; Shuichi Ota; Souichi Shiratori; Yasushi Onishi; Yoshinobu Kanda; Masashi Sawa; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Journal:  Blood Adv       Date:  2021-01-26

Review 3.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

4.  Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.

Authors:  Arie Barlev; Vincent W Lin; Aaron Katz; Kuolung Hu; Ze Cong; Beth Barber
Journal:  Adv Ther       Date:  2016-11-21       Impact factor: 3.845

5.  Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).

Authors:  Satoshi Nishiwaki; Isamu Sugiura; Yasuhiko Miyata; Shigeki Saito; Masashi Sawa; Tetsuya Nishida; Koichi Miyamura; Yachiyo Kuwatsuka; Akio Kohno; Masaaki Yuge; Masanobu Kasai; Hiroatsu Iida; Shingo Kurahashi; Masahide Osaki; Tatsunori Goto; Seitaro Terakura; Makoto Murata; Hiroyoshi Nishikawa; Hitoshi Kiyoi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.